- Information
- AI Chat
Var det här dokumentet användbart?
Dangers of Escalation of Commitment
Kurs: Accounting and Finance
73 Dokument
Studenter delade 73 dokument i den här kursen
Universitet: Birmingham City University
Var det här dokumentet användbart?
Dangers of Escalation of
Commitment
This report analyses the issue of escalation of commitment to a course of
action from the perspective of the pharmaceutical industry. Escalation can
be defined as a situation where a failing venture is supplied with
additional resources beyond the point of feasibility. As such, escalation
carries substantial dangers for organisations by generating avoidable
economic losses. The report inquiries into the generic causes of escalation
by examining subject literature. Accordingly psychological, social,
organisational and project-specific factors are identified as common
escalation activators. Exploration into the particulars of the said industry
categorises profitability issues, market performance concerns, maturing
products portfolio alongside development pipeline conditions as features
amplifying pharma companies' vulnerability to escalation. The point is
supported by real-life case examples located in the appendix.
Appreciation of escalation causes allows for development of effective
prevention policies. The report suggests preventive measures aimed at
reducing the occurrence of escalation triggers, such as challenging the
individual and social causes. Approaches for reducing other factors'
impact on decision-making are outlined in the form of strategy alteration
as well as process management policies. The report finalises with
suggestions on escalating situations management.
Statement of Reference
The aim of this 2000-word report is to inquiry the causes and dangers of
escalation of commitment to a course of action from the perspective of
pharmaceutical companies.
This report is to assess the dangers of escalation of commitment to a
chosen course of action through the perspective of pharmaceutical
companies. In order to achieve the aim set, the paper first analyses the
definition and threats arising from the phenomenon of escalation.
Next, following the framework proposed by Ross & Staw (1993) generic
causes of escalation are summarised. Subsequently, the report looks at
industry- and drug development-specific escalation triggers in an attempt
to identify why the pharmaceutical companies are particularly vulnerable
to the dangers of escalation of commitment.
Then, escalation prevention provisions organised around tackling
previously identified triggers are outlined. The report concludes with
suggestions concerning the issue of escalating situation management.